Brief: Theravance Biopharma Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million
02/06/2025 13:10
June 2 (Reuters) - GSK plc GSK.L: THERAVANCE BIOPHARMA, INC. SELLS REMAINING ROYALTY INTEREST IN TRELEGY ELLIPTA TO GSK FOR $225 MILLION THERAVANCE BIOPHARMA INC - FINANCIAL GUIDANCE FOR 2025 REMAINS UNCHANGED THERAVANCE BIOPHARMA INC - RETAINS RIGHTS TO UP TO $150 MILLION IN MILESTONES FROM ROYALTY PHARMA ON TRELEGY ELLIPTA NET SALES IN 2025 & 2026 Source text: ID:nPnbyNcpNa Further company coverage: GSK.L ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theravance Biopharma
See all newsIreland's Theravance Biopharma Q1 revenue beats estimates on YUPELRI growth
Ireland's Theravance Biopharma Q4 revenue misses expectations
Corrected: BRIEF-Theravance Biopharma Q4 Operating Income USD 20.012 Million
U.S. STOCKS ON THE MOVE-Versant Media Group, Lithium miners, Expedia Group
U.S. STOCKS ON THE MOVE-Expedia Group, Blue Owl Capital, Enphase Energy